-
sodium (2S,5R,6R)-6-[3-(2-chlorophenyl)-5-methyl-1,2-oxazole-4-amido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate hydrate
-
ChemBase ID:
73105
-
Molecular Formular:
C19H19ClN3NaO6S
-
Molecular Mass:
475.87843
-
Monoisotopic Mass:
475.0580783
-
SMILES and InChIs
SMILES:
[C@H]1(C(=O)N2[C@@H]1SC([C@@H]2C(=O)[O-])(C)C)NC(=O)c1c(onc1c1ccccc1Cl)C.[Na+].O
Canonical SMILES:
[O-]C(=O)[C@@H]1N2C(=O)[C@H]([C@H]2SC1(C)C)NC(=O)c1c(C)onc1c1ccccc1Cl.O.[Na+]
InChI:
InChI=1S/C19H18ClN3O5S.Na.H2O/c1-8-11(12(22-28-8)9-6-4-5-7-10(9)20)15(24)21-13-16(25)23-14(18(26)27)19(2,3)29-17(13)23;;/h4-7,13-14,17H,1-3H3,(H,21,24)(H,26,27);;1H2/q;+1;/p-1/t13-,14+,17-;;/m1../s1
InChIKey:
KCUWTKOTPIUBRI-VICXVTCVSA-M
-
Cite this record
CBID:73105 http://www.chembase.cn/molecule-73105.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
sodium (2S,5R,6R)-6-[3-(2-chlorophenyl)-5-methyl-1,2-oxazole-4-amido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate hydrate
|
|
|
IUPAC Traditional name
|
sodium cloxacillin(1-) hydrate
|
|
|
Synonyms
|
Cloxapen
|
Cloxacap
|
Orbenin
|
Cloxacillin sodium
|
|
|
CAS Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
Acid pKa
|
3.7497845
|
H Acceptors
|
5
|
H Donor
|
1
|
LogD (pH = 5.5)
|
0.55099535
|
LogD (pH = 7.4)
|
-0.9830029
|
Log P
|
2.3017397
|
Molar Refractivity
|
117.4742 cm3
|
Polarizability
|
41.823692 Å3
|
Polar Surface Area
|
115.57 Å2
|
Rotatable Bonds
|
4
|
Lipinski's Rule of Five
|
true
|
PROPERTIES
PROPERTIES
Safety Information
Bioassay(PubChem)
Storage Condition
|
-20°C
|
Show
data source
|
|
DETAILS
DETAILS
Selleck Chemicals
Selleck Chemicals -
S2564
|
Research Area: Infection Biological Activity: Cloxacillin sodium (Cloxacap) is a sodium salt of cloxacillin that is a penicillinase-resistant, acid resistant, semi-synthetic penicillin. Cloxacillin sodium exerts a bactericidal action against susceptible microorganisms during the stage of active multiplication. Cloxacillin sodium acts through the inhibition of biosynthesis of cell wall mucopeptides. Cloxacillin sodium is readily absorbed following i.m. administration and rapidly reaches therapeutically effective blood levels. Serum levels are approximately proportional to dosage. Peak plasma concentrations of 15 µg/ml have been observed 30 minutes after an i.m. injection of cloxacillin (Cloxapen, Cloxacap and Orbenin) 500 mg; plasma concentrations may be doubled by administration of a doubled dose. At the end of a 3-hour i.v. infusion of cloxacillin (Cloxapen, Cloxacap and Orbenin) 250 mg given to normal subjects, its plasma concentrations were 15 µg/ml. After 2 hours, plasma concentrations were 0.6 µg/ml. [1] |
PATENTS
PATENTS
PubChem Patent
Google Patent